Cell-targeted cytotoxics: a new generation of cytotoxic agents for cancer treatment
Tóm tắt
Từ khóa
Tài liệu tham khảo
Annereau JP, Brel V, Dumontet C, Guminski Y, Imbert T, Broussas M, Vispé S, Bréand S, Guilbaud N, Barret JM, Bailly C (2010) A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. Leuk Res 34:1383–1389
Ayala-López W, Xia W, Varghese B, Low PS (2010) Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med 51:768–774
Bailly C (2009) Ready for a comeback of natural products in oncology. Biochem Pharmacol 77:1447–1457
Bailly C (2012) Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Chem Rev 112:3611–3640
Ballot C, Jendoubi M, Kluza J, Jonneaux A, Laine W, Formstecher P, Bailly C, Marchetti P (2012) Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II. Apoptosis 17:364–376
Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C (2008) F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 68:9845–9853
Brel V, Annereau JP, Vispé S, Kruczynski A, Bailly C, Guilbaud N (2011) Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. Biochem Pharmacol 82:1843–1852
Cagle PT, Zhai QJ, Murphy L, Low PS (2013) Folate Receptor in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: potential Target for Folate-Linked Therapeutic Agents. Arch Pathol Lab Med 137:241–244
Chelouah S, Monod-Wissler C, Bailly C, Barret JM, Guilbaud N, Vispé S, Käs E (2011) An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II. PLoS ONE 6:e23597
Chen YL, Chang MC, Huang CY, Chiang YC, Lin HW, Chen CA, Hsieh CY, Cheng WF (2012) Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6:360–369
Corcé V, Morin E, Guihéneuf S, Renault E, Renaud S, Cannie I, Tripier R, Lima LM, Julienne K, Gouin SG, Loréal O, Deniaud D, Gaboriau F (2012) Polyaminoquinoline iron chelators for vectorization of antiproliferative agents: design, synthesis, and validation. Bioconjug Chem 23:1952–1968
Crane LM, Arts HJ, van Oosten M, Low PS, van der Zee AG, van Dam GM, Bart J (2012) The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) 35:9–18
Daigle ND, Carpentier GA, Frenette-Cotton R, Simard MG, Lefoll MH, Noël M, Caron L, Noël J, Isenring P (2009) Molecular characterization of a human cation-Cl- cotransporter (SLC12A8A, CCC9A) that promotes polyamine and amino acid transport. J Cell Physiol 220:680–689
D’Angelica M, Ammori J, Gonen M, Klimstra DS, Low PS, Murphy L, Weiser MR, Paty PB, Fong Y, Dematteo RP, Allen P, Jarnagin WR, Shia J (2011) Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Mod Pathol 24:1221–1228
Danhier F, Breton AL, Préat V (2012) RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Mol Pharm 9:2961–2973
Dao KL, Hanson RN (2012) Targeting the estrogen receptor using steroid-therapeutic drug conjugates (Hybrids). Bioconjug Chem 23:2139–2158
Dosio F, Milla P, Cattel L (2010) EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 11:1424–1433
Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 50:3240–3249
Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 65:11721–11728
Gokhale M, Thakur A, Rinaldi F (2012) Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev Ind Pharm (in press)
Guminski Y, Grousseaud M, Cugnasse S, Brel V, Annereau JP, Vispé S, Guilbaud N, Barret JM, Bailly C, Imbert T (2009) Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system. Bioorg Med Chem Lett 19:2474–2477
Heffner L Jr (2011) A new formulation of vincristine for acute lymphoblastic leukemia. Clin Adv Hematol Oncol 9:314–316
Henne WA, Rothenbuhler R, Ayala-Lopez W, Xia W, Varghese B, Low PS (2012a) Imaging sites of infection using a 99 mTc-labeled folate conjugate targeted to folate receptor positive macrophages. Mol Pharm 9:1435–1440
Henne WA, Kularatne SA, Ayala-López W, Doorneweerd DD, Stinnette TW, Lu Y, Low PS (2012b) Synthesis and activity of folate conjugated didemnin B for potential treatment of inflammatory diseases. Bioorg Med Chem Lett 22:709–712
Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD (2012) Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7:e31970
Ismael GF, Rosa DD, Mano MS, Awada A (2008) Novel cytotoxic drugs: old challenges, new solutions. Cancer Treat Rev 34:81–91
Jeter JM, Alberts DS (2012) Difluoromethylornithine: the proof is in the polyamines. Cancer Prev Res (Phila) 5:1341–1344
Kamen BA, Smith AK (2012) Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 70:113–120
Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N (2011) Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. Invest New Drugs 29:9–21
Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N (2002) Synthesis and biological evaluation of EC20: a new folate-derived, (99 m)Tc-based radiopharmaceutical. Bioconjug Chem 13:1200–1210
Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, Vetzel M (2007a) Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 121:1585–1592
Leamon CP, Reddy JA, Vlahov IR, Westrick E, Dawson A, Dorton R, Vetzel M, Santhapuram HK, Wang Y (2007b) Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 4:659–667
Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I (2008) Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res 68:9839–9844
Leamon CP, Reddy JA, Klein PJ, Vlahov IR, Dorton R, Bloomfield A, Nelson M, Westrick E, Parker N, Bruna K, Vetzel M, Gehrke M, Nicoson JS, Messmann RA, LoRusso PM, Sausville EA (2011) Reducing undesirable hepatic clearance of a tumor-targeted Vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther 336:336–343
Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P (2009) Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 49:1467–1476
Li M, Li Q, Zhang YH, Tian ZY, Ma HX, Zhao J, Xie SQ, Wang CJ (2013) Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro. Anticancer Drugs 24:32–42
Liu X, Ma S, Yao Y, Li G, Feng M, Deng K, Dai C, Cai F, Li Y, Zhang B, Wang R (2012) Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior. Neurosurgery 70:1274–1280
Lorusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, Li J, Heath EI, Malburg LM, Klein PJ, Leamon CP, Messmann RA, Sausville EA (2012) Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors. J Clin Oncol 30:4011–4016
Low PS, Antony AC (2004) Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 56:1055–1058
Low PS, Kularatne SA (2009) Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 13:256–262
Lu Y, Low PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675–693
Matteson EL, Lowe VJ, Prendergast FG, Crowson CS, Moder KG, Morgenstern DE, Messmann RA, Low PS (2009) Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 27:253–259
Mezo G, Manea M (2010) Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv 7:79–96
Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II (2012) High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR mutation. J Thorac Oncol 7:833–840
Ojima I, Zuniga ES, Berger WT, Seitz JD (2012) Tumor-targeting drug delivery of new-generation taxoids. Future Med Chem 4:33–50
O’Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Somers EB, Vachani A (2012) Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 3:414–425
Palmer AJ, Ghani RA, Kaur N, Phanstiel O, Wallace HM (2009) A putrescine-anthracene conjugate: a paradigm for selective drug delivery. Biochem J 424:431–438
Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284–293
Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A (2011) 99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation. Eur J Nucl Med Mol Imaging 38:1832–1841
Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, Aibgirhio FI, Golovko O, Jackman AL, Aboagye EO (2008) Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 68:3827–3834
Pribble P, Edelman MJ (2012) EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs 21:755–761
Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP (2004) Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 45:857–866
Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP (2006) Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 58:229–236
Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP (2007) Preclinical evaluation of EC145, a folate-Vinca alkaloid conjugate. Cancer Res 67:4434–4442
Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, Westrick E, Klein PJ, Wang Y, Vlahov IR, Leamon CP (2009) In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol Pharm 6:1518–1525
Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lönnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL (2010) A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone 47:12–22
Schutz FA, Bellmunt J, Rosenberg JE, Choueiri TK (2011) Vinflunine: drug safety evaluation of this novel synthetic Vinca alkaloid. Expert Opin Drug Saf 10:645–653
Shillingford JM, Leamon CP, Vlahov IR, Weimbs T (2012) Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 23:1674–1681
Teng L, Xie J, Teng L, Lee RJ (2012) Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv 9:901–908
Tomasi S, Renault J, Martin B, Duhieu S, Cerec V, Le Roch M, Uriac P, Delcros JG (2010) Targeting the polyamine transport system with benzazepine- and azepine-polyamine conjugates. J Med Chem 53:7647–7663
Vaitilingam B, Chelvam V, Kularatne SA, Poh S, Ayala-Lopez W, Low PS (2012) A folate receptor-α-specific ligand that targets cancer tissue and not sites of inflammation. J Nucl Med 53:1127–1134
Vida N, Svobodová H, Rárová L, Drašar P, Saman D, Cvačka J, Wimmer Z (2012) Polyamine conjugates of stigmasterol. Steroids 77:1212–1218
Vlahov IR, Leamon CP (2012) Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem 23:1357–1369
Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP (2006) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16:5093–5096
Vlahov IR, Santhapuram HK, You F, Wang Y, Kleindl PJ, Hahn SJ, Vaughn JF, Reno DS, Leamon CP (2010a) Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates. J Org Chem 75:3685–3691
Vlahov IR, Vite GD, Kleindl PJ, Wang Y, Santhapuram HK, You F, Howard SJ, Kim SH, Lee FF, Leamon CP (2010b) Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. Bioorg Med Chem Lett 20:4578–4581